Login / Signup

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

Catherine Saint-Laurent ThibaultDivya MoorjaneyMichael L GanzBruce SillShalini HedeYong YuanBoris Gorsh
Published in: Journal of medical economics (2017)
DCV + SOF is a dominant option compared with SOF + RBV in the US for the overall GT 3 HCV patient population.
Keyphrases
  • hepatitis c virus
  • human immunodeficiency virus
  • combination therapy
  • hepatitis c virus infection
  • case report
  • hiv infected
  • antiretroviral therapy